Evidence map›Paper›PMID 29732003›Full record

ArticleOncotarget2018

Single-cell genetic analysis validates cytopathological identification of circulating cancer cells in patients with clear cell renal cell carcinoma.

Lucile Broncy, Basma Ben Njima, Arnaud Méjean, Christophe Béroud, Khaled Ben Romdhane, Marius Ilie, Veronique Hofman, Jane Muret, Paul Hofman, Habiba Chaabouni Bouhamed and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Observational
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Lucile BroncyINSERM Unit 1151, Faculté de Médecine Paris Descartes, Paris, France.
Basma Ben NjimaGenetics and Pathology Departments, University of Tunis, Tunis, Tunisia.
Arnaud MéjeanService d'Urologie, Hôpital Européen Georges Pompidou, Paris, France.
Christophe BéroudAix Marseille University, INSERM, MMG, Marseille, France.
Khaled Ben RomdhaneGenetics and Pathology Departments, University of Tunis, Tunis, Tunisia.
Marius IlieLaboratoire de pathologie clinique et Biobank BB-0033-00025, Centre Hospitalo-Universitaire de Nice, Nice, France.
Veronique HofmanLaboratoire de pathologie clinique et Biobank BB-0033-00025, Centre Hospitalo-Universitaire de Nice, Nice, France.
Jane MuretInstitut Curie, PSL Research University, Département d'Anesthésie Réanimation Douleur, Paris, France.
Paul HofmanLaboratoire de pathologie clinique et Biobank BB-0033-00025, Centre Hospitalo-Universitaire de Nice, Nice, France.
Habiba Chaabouni BouhamedGenetics and Pathology Departments, University of Tunis, Tunis, Tunisia.
And Patrizia Paterlini-BréchotINSERM Unit 1151, Faculté de Médecine Paris Descartes, Paris, France.
Centre Hospitalier Universitaire de Nice · FRTunis University · TNHôpital Européen · FRHôpital Necker-Enfants Malades · FRInserm · FRUniversité Paris Cité · FRUniversité Paris Sciences et Lettres · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextCirculating Rare Cells (CRC) are non-haematological cells circulating in blood. They include Circulating Cancer Cells (CCC) and cells with uncertain malignant features (CRC-UMF) according to cytomorphology. Clear cell renal cell carcinomas frequently bear a mutated Von Hippel-Lindau (VHL) gene.

aimTo match blind genetic analysis of CRC and tumor samples with CRC cytopathological diagnosis.

results29/30 patients harboured CRC (20 harboured CCC, 29 CRC-UMF) and 25/29 patients carried VHL mutations in their tumour. 205 single CRC (64 CCC, 141 CRC-UMF) provided genetic data. 57/57 CCC and 104/125 CRC-UMF from the 25 patients with VHL-mutated tumor carried the same VHL mutation detected in the tumor. Seven CCC and 16 CRC-UMF did not carry VHL mutations but were found in patients with wild-type VHL tumor tissue.

conclusionsAll the CCC and 83,2% (104/125) of the CRC-UMF were found to carry the same VHL mutation identified in the corresponding tumorous tissue, validating cytopathological identification of CCC in patients with clear cell renal cell carcinoma.

methodsThe blood of 30 patients with clear cell renal cell carcinoma was treated by ISET

Indexed as

circulating cancer cellsclear cell renal cell carcinomaISET® (Isolation by Size of Tumour/Trophoblastic Cells) technologyliquid biopsyVHL mutation

Identifiers

PMID29732003
PMCPMC5929446
OpenAlexW2800957885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.